Ayala Pharmaceuticals, Inc. (AYLA)
| Market Cap | 167.39M |
| Revenue (ttm) | 3.08M |
| Net Income (ttm) | n/a |
| Shares Out | 12.66M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $13.15 |
| Previous Close | $13.10 |
| Change ($) | 0.05 |
| Change (%) | 0.38% |
| Day's Open | 12.99 |
| Day's Range | 12.70 - 13.90 |
| Day's Volume | 34,693 |
| 52-Week Range | 8.80 - 15.92 |
Ayala Pharmaceuticals (AYLA) saw a big move last session, as its shares jumped more than 13% on the day, amid huge volumes.
REHOVOT, Israel and WILMINGTON, Del., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing ...
REHOVOT, Israel and WILMINGTON, Del., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing ...
- FDA Agreement from End-of-Phase 1 Meeting to Advance to Potential Registrational Study -
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion t...
- Presented N ew P ositive I nterim D ata from 4mg C ohort of Phase 2 ACCURACY S tudy of AL101 for the T reatment of R/M ACC at European Society for Medical Oncology 2020 -
REHOVOT, Israel and WILMINGTON, Del., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing ...
After a fast and furious week of activity, the IPO market is slated for a brief intermission in the coming week due to the approaching presidential election. Currently, there are no regular wa...
– Interim data showed meaningful clinical activity of AL101 4mg monotherapy with deep responses and 68% disease control rate
REHOVOT, Israel and WILMINGTON, Del., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializi...
REHOVOT, Israel and WILMINGTON, Del., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializi...
REHOVOT, Israel and WILMINGTON, Del., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA) (the Company or Ayala), a clinical-stage oncology company focused on develo...
– New interim data from Phase 2 ACCURACY study of AL101 for the treatment of R/M ACC to be presented at ESMO 2020 –
REHOVOT, Israel and WILMINGTON, Del., July 27, 2020 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializin...
– Completed upsized initial public offering raising a total of $59.1 million in gross proceeds
The Phase 2 study of Ayala Pharmaceuticals Inc’s (NASDAQ: AYLA) AL101 candidate is scheduled to begin in the back half of this year.
About AYLA
Ayala Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule G... [Read more...]
| Industry Biotechnology | IPO Date May 8, 2020 |
| CEO Dr. Roni Mamluk | Employees 31 |
| Stock Exchange NASDAQ | Ticker Symbol AYLA |
Analyst Forecasts
According to 5 analysts, the average rating for AYLA stock is "Buy." The 12-month stock price forecast is 21.60, which is an increase of 64.26% from the latest price.